Asymmetric Diabetic Retinopathy: DME in One Eye, High-Risk PDR in the Other
A 64-year-old man with a 15-year history of type 2 diabetes presents for a routine eye examination. He takes metformin and glipizide but admits poor dietary adherence; his HbA1c is 9.6% and blood pressure is 152/88 mmHg. He has no visual complaints. Visual acuity is 20/60 OD and 20/25 OS. Dilated fundus examination of the right eye shows microaneurysms, dot-blot hemorrhages, cotton-wool spots, and a cluster of hard exudates in the macula; OCT shows a central subfield thickness of 430 µm. The left eye shows neovascularization of the disc, a preretinal hemorrhage, and no macular edema. He asks whether he needs laser or an injection, and whether both eyes can wait until his insurance approves treatment.
1. Classify the diabetic retinopathy in each eye and outline your management plan, including the urgency of each intervention.
Read the worked answer
Right eye: moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema (DME), based on the central subfield thickness of 430 µm and macular hard exudates. Left eye: proliferative diabetic retinopathy with neovascularization of the disc and preretinal hemorrhage; this is high-risk PDR because of the disc neovascularization and hemorrhage.
Right eye management: anti-VEGF therapy is first-line for center-involving DME. Agents such as aflibercept, ranibizumab, or bevacizumab are appropriate; choose based on availability, cost, and comorbidity. Treat promptly-within days to a couple of weeks-rather than waiting for insurance approval, because prolonged edema can cause irreversible macular damage. If anti-VEGF is not feasible, focal/grid laser can be considered, but it is less effective for center-involving edema and carries a risk of central scotoma.
Left eye management: high-risk PDR requires prompt panretinal photocoagulation (PRP), ideally within 1–2 weeks. Anti-VEGF can be used as an adjunct to reduce neovascularization and vitreous hemorrhage risk, but PRP remains the definitive treatment for PDR. Do not delay PRP while awaiting anti-VEGF. If vitreous hemorrhage obscures the view or tractional retinal detachment develops, refer urgently for vitrectomy.
Both eyes: coordinate care with a retina specialist and communicate urgency to the patient. The asymmetry does not change the indication for treating each eye on its own merits.
2. How would you coordinate systemic management and follow-up for this patient, and what would you tell him about the relationship between his diabetes control and his eyes?
Read the worked answer
Systemic coordination: communicate directly with his primary care physician about the retinopathy, HbA1c of 9.6%, and blood pressure of 152/88 mmHg. Improved glycemic control reduces progression, but it must be achieved gradually; rapid tightening of control can transiently worsen retinopathy. Blood pressure control and lipid management also matter, especially for macular edema. Screen for renal disease because nephropathy and retinopathy often coexist. Recommend a dilated eye examination at least every 3–6 months while active treatment is ongoing.
Patient counseling: explain that high blood sugar damages retinal capillaries, causing both leakage (macular edema) and growth of abnormal vessels (proliferative disease). The right eye has leakage that threatens central vision; the left eye has abnormal vessels that can bleed or detach the retina. Emphasize that treatment is urgent even though he has no symptoms. Warn about symptoms of vitreous hemorrhage-sudden floaters, webs, or vision loss-and instruct him to call immediately.
Follow-up: after anti-VEGF, see him in about 4 weeks with OCT to assess response; after PRP, see him in 2–4 weeks to check for regression and complications. Repeat PRP as needed. If edema persists despite anti-VEGF, consider switching agents or adding focal laser. Maintain a team approach with his primary care physician and retina specialist.
3. The patient says he cannot afford anti-VEGF injections and may miss follow-up visits. How does that change your treatment plan?
Read the worked answer
Reassess the plan around adherence and cost. For the right eye with center-involving DME, anti-VEGF is still the best option for visual improvement, so first explore assistance programs, insurance appeals, and generic bevacizumab, which is often the lowest-cost anti-VEGF. If injections truly cannot be delivered, focal/grid laser is a reasonable fallback. It is less effective for center-involving edema and may cause paracentral scotoma, but it can reduce edema and is durable. Use modified grid laser, avoid treating the foveal avascular zone, and counsel about expected visual limitations.
For the left eye with high-risk PDR, PRP is the preferred durable treatment because it usually requires only a few sessions and does not depend on monthly injections. Complete PRP in a timely manner; if follow-up is unreliable, PRP is more forgiving than a monthly anti-VEGF schedule. If there is concurrent macular edema in the future, treat edema first or concurrently depending on severity, because PRP can worsen edema.
Address barriers: involve a social worker or patient navigator, simplify the drop regimen, and consolidate appointments. Document the discussion. If the patient misses visits, contact him and reschedule rather than assuming he has abandoned care. The key judgment is to choose the most durable, least visit-dependent therapy while still treating sight-threatening disease.